Why Halozyme Therapeutics Shares should scare you more than Osama Bin Laden

Halozyme Therapeutics, Inc. is a biopharmaceutical company developing and commercializing products that advance patient care. The Company’s research focuses on targeting the extracellular matrix an area outside the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Its research focuses primarily on human enzymes that alter the extracellular matrix. Its recombinant human hyaluronidase or rHuPH20, temporarily degrades hyaluronan (HA), a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. It also focuses on developing novel enzymes that may target other matrix structures for therapeutic benefit. Its Enhanze technology is the platform for the delivery small and large molecules. Halozyme Therapeu (NGM:HALO) is +1.54 - +24.02% from the previous close of $6.41. It traded between $7.76 - 8.65 with total traded volume of 4892621 shares. At Current Market Price, HALO is in distance of +34.54% from its 50-day Moving Average price of $5.9091 and -6.33% from its 200-day Moving Average price of $8.4872.

Can HALO Bounce Back After The Recent Slump? Find Out Here

As you can see by Friday's action, the FDA's ruling has considerably more bearing on the unprofitable Halozyme than it does on ViroPharma, whose Cinryze is already pumping out profits. As for me, I'm not nearly as excited about the news -- at least not as excited as investors seem to be. In December, I noted Halozyme's lofty valuation as a reason to avoid the stock, and I'm sticking with that assertion even today. With losses expected well into 2014 and possibly beyond, I see little reason to chase Halozyme higher.Craving more input? Start by adding Halozyme Therapeutics to your free and personalized watchlist so you can keep up on the latest news with the company.